Perspective Therapeutics, Inc. (CATX)

Price$4.55

Favorite Metrics

Price vs S&P 500 (26W)-22.33%

Price vs S&P 500 (4W)-15.11%

Market Capitalization$478.52M

All Metrics

Book Value / Share (Quarterly)$2.79

P/TBV (Annual)1.22x

Revenue Growth (3Y)-37.09%

Cash Flow / Share (Quarterly)$-1.28

Price vs S&P 500 (YTD)48.59%

Gross Margin (TTM)22.97%

Net Profit Margin (TTM)-11665.27%

EPS (TTM)$-1.39

10-Day Avg Trading Volume0.74M

EPS Excl Extra (TTM)$-1.39

Revenue Growth (5Y)-38.50%

EPS (Annual)$-1.40

ROI (Annual)-49.42%

Gross Margin (Annual)23.10%

Net Profit Margin (5Y Avg)-4127.01%

Cash / Share (Quarterly)$1.95

Revenue Growth QoQ (YoY)-81.62%

ROA (Last FY)-38.63%

Revenue Growth TTM (YoY)-39.20%

EBITD / Share (TTM)$-1.48

ROE (5Y Avg)-32.85%

Operating Margin (TTM)-12846.61%

Cash Flow / Share (Annual)$-1.28

P/B Ratio2.31x

P/B Ratio (Quarterly)0.99x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)508.50x

Net Interest Coverage (TTM)-3.35x

ROA (TTM)-34.32%

EPS Incl Extra (Annual)$-1.40

Current Ratio (Annual)5.17x

Quick Ratio (Quarterly)5.08x

3-Month Avg Trading Volume2.75M

52-Week Price Return127.03%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.25

P/S Ratio (Annual)541.31x

Asset Turnover (Annual)0.00x

52-Week High$6.16

Operating Margin (5Y Avg)-4448.67%

EPS Excl Extra (Annual)$-1.40

CapEx CAGR (5Y)99.28%

26-Week Price Return-13.58%

Quick Ratio (Annual)5.08x

13-Week Price Return60.31%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.17x

Enterprise Value$449.517

Revenue / Share Growth (5Y)-34.13%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)5.19x

Pretax Margin (Annual)-11813.12%

Cash / Share (Annual)$1.95

3-Month Return Std Dev162.74%

Gross Margin (5Y Avg)42.29%

Net Income / Employee (TTM)$-1

ROE (Last FY)-49.81%

Net Interest Coverage (Annual)-2.38x

EPS Basic Excl Extra (Annual)$-1.40

Receivables Turnover (TTM)14.49x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$-1.39

Receivables Turnover (Annual)14.49x

ROI (TTM)-41.00%

P/S Ratio (TTM)541.31x

Pretax Margin (5Y Avg)-4083.08%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$2.25

Price vs S&P 500 (52W)91.93%

Year-to-Date Return52.73%

5-Day Price Return-3.45%

EPS Normalized (Annual)$-1.40

ROA (5Y Avg)-26.66%

Net Profit Margin (Annual)-11665.27%

Month-to-Date Return0.72%

Cash Flow / Share (TTM)$-0.06

EBITD / Share (Annual)$-1.48

Operating Margin (Annual)-12846.61%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-32.46%

LT Debt / Equity (Quarterly)0.01x

EPS Basic Excl Extra (TTM)$-1.39

P/TBV (Quarterly)1.22x

P/B Ratio (Annual)0.99x

Inventory Turnover (TTM)4.82x

Pretax Margin (TTM)-11813.12%

Book Value / Share (Annual)$2.79

Price vs S&P 500 (13W)57.44%

Beta1.82x

Revenue / Share (TTM)$0.01

ROE (TTM)-41.27%

52-Week Low$1.75

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.11

4.10

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CATXPerspective Therapeutics, Inc.	541.31x	-39.20%	22.97%	—	$4.55
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Perspective Therapeutics develops targeted radiopharmaceuticals using Lead-212, an alpha-emitting isotope designed to deliver radiation directly to cancer cells. The company's approach aims to improve treatment efficacy while reducing harm to healthy tissue. This technology addresses a significant market need for more selective cancer therapies across multiple tumor types.